Gsa Capital Partners LLP Eiger Bio Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.28 - $0.93 $19,653 - $65,276	70,190 Added 24.57%	355,867 $106,000
Q2 2023 Aug 14, 2023	BUY	$0.55 - $1.26 $49,595 - $113,617	90,173 Added 46.12%	285,677 $199,000
Q1 2023 May 12, 2023	BUY	$0.89 - $2.52 $104,550 - $296,031	117,473 Added 150.55%	195,504 $175,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $7.48 $79,591 - $583,671	78,031 New	78,031 $92,000
Q1 2022 May 11, 2022	SELL	$3.84 - $9.74 $710,323 - $1.8 Million	-184,980 Closed	0 $0

Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $188,390 - $301,351	36,795 Added 24.83%	184,980 $960,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $456,063 - $621,284	68,273 Added 85.44%	148,185 $990,000
Q2 2021 Aug 05, 2021	BUY	$7.82 - $9.23 $417,095 - $492,300	53,337 Added 200.7%	79,912 $681,000
Q1 2021 May 10, 2021	SELL	$8.44 - $12.66 $919,630 - $1.38 Million	-108,961 Reduced 80.39%	26,575 $235,000
Q4 2020 Feb 03, 2021	BUY	$7.98 - $12.29 $56,219 - $86,583	7,045 Added 5.48%	135,536 $1.67 Million
Q3 2020 Nov 06, 2020	BUY	$7.96 - $12.42 $841,284 - $1.31 Million	105,689 Added 463.51%	128,491 $1.05 Million
Q2 2020 Aug 11, 2020	BUY	$5.4 - $13.37 $123,130 - $304,862	22,802 New	22,802 $219,000
Q1 2020 May 12, 2020	SELL	$4.91 - $14.7 $63,412 - $189,850	-12,915 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$9.77 - $15.66 $63,690 - $102,087	-6,519 Reduced 33.54%	12,915 $192,000
Q3 2019 Nov 12, 2019	SELL	$9.59 - $12.0 $253,991 - $317,820	-26,485 Reduced 57.68%	19,434 $199,000
Q2 2019 Aug 06, 2019	BUY	$9.54 - $14.96 $438,067 - $686,948	45,919 New	45,919 $487,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.